Phaseline

Targets › JAK

JAK: drug programs, companies and trials

2 programs from 2 companies in 2 trials: 2 Phase 2; Oncology; next expected readout Dec 2026.

Open in Phaseline: the race on JAK, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Eli LillyLY2784544
JAK inhibitor
JAKPhase 2Neoplasms, HematologicDec 2026
Renmin Hospital of Wuhan UniversityIvarmacitinib Sulfate
JAK/STAT signaling inhibitor
JAKPhase 2Refractory Metastatic Colorectal CancerDec 2027

Conditions

Refractory Metastatic Colorectal Cancer (1) Neoplasms, Hematologic (1)

Modalities

mixed (1), small molecule (1)

Companies

Renmin Hospital of Wuhan University (1) Eli Lilly (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.